Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hubei Meilin Pharmaceutical is a comprehensive pharmaceutical enterprise located in Jingmen, Hubei Province, China. Established in 2004, the company specializes in the research, development, and large-scale production of chemical drugs and traditional Chinese medicines. Its manufacturing facilities are GMP-certified and include production lines for tablets, capsules, granules, and oral liquids, with a particular focus on pediatric and respiratory health. The company's product portfolio features widely used over-the-counter medications such as ibuprofen and paracetamol formulations. Hubei Meilin operates as an independent entity, distinct from the Meilin brand marketed by Johnson & Johnson in China, and serves as a key regional supplier of generic pharmaceuticals. The company is committed to providing high-quality, affordable healthcare products to the domestic Chinese market and international clients.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hubei Meilin Pharmaceutical.